Head to head
Amycretin against CagriSema
Two answers to the same idea, that amylin plus GLP-1 does more than GLP-1 alone. One puts both activities in a single molecule; the other combines two molecules in one injection. Neither is approved and no trial has compared them.
Column A
AmycretinAmycretin (unimolecular GLP-1 / amylin agonist)
Novo Nordisk's single-molecule GLP-1 and amylin agonist, in oral and injectable forms, that showed strong early weight loss and is heading to Phase 3.
Column B
CagriSemaCagriSema (cagrilintide + semaglutide)
A fixed combination of the amylin analogue cagrilintide and semaglutide that produced about 23% weight loss in Phase 3 and has been filed for FDA approval.
Side by side, on the facts we can check
| Attribute | Amycretin | CagriSema |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | Investigational (Phase 3 AMAZE program started February 2026) | Investigational; NDA submitted to the FDA in December 2025 (REDEFINE 1 and 2); decision expected 2026 |
| Half-life | Supports weekly (injectable) dosing | ~7 days (weekly dosing) |
| Molecular weight | Not disclosed | Mixture; cagrilintide 4,409 Da plus semaglutide 4,113.6 Da |
| Mechanism | A single molecule that agonizes both the GLP-1 and amylin receptors to suppress appetite through two complementary pathways. | Simultaneously agonizes amylin receptors (satiety) and the GLP-1 receptor (appetite, insulin, gastric emptying) for additive weight loss. |
| Human studies cited | 3 | 3 |
| Legal status, US | Investigational, not approved | Investigational, not approved |
Frequently asked questions
What is the difference between Amycretin and CagriSema?
Amycretin: Novo Nordisk's single-molecule GLP-1 and amylin agonist, in oral and injectable forms, that showed strong early weight loss and is heading to Phase 3. CagriSema: A fixed combination of the amylin analogue cagrilintide and semaglutide that produced about 23% weight loss in Phase 3 and has been filed for FDA approval.
Which has stronger research evidence, Amycretin or CagriSema?
This database does not grade compounds. It counts what was run in people: 3 of the 3 studies cited on the Amycretin profile were human work, against 3 of 3 for CagriSema. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are Amycretin and CagriSema FDA-approved?
Amycretin: Investigational (Phase 3 AMAZE program started February 2026). CagriSema: Investigational; NDA submitted to the FDA in December 2025 (REDEFINE 1 and 2); decision expected 2026.
Related posts
Blog articles that cover Amycretin or CagriSema, newest first.
- Dispatch / Sep 12, 2026 / 8 minDispatch 001: Five Retatrutide Phase 3 Trials Have Finished And None Has Posted Results
- Metabolic / Sep 8, 2026 / 9 minMariTide (Maridebart Cafraglutide): The Once-Monthly GLP-1 Agonist and GIP Blocker, Explained
- Metabolic / Sep 8, 2026 / 9 minCagrilintide: The Amylin Half of CagriSema, and Why People Search 'Cagrilintide with Retatrutide'
- Metabolic / Sep 8, 2026 / 9 minRetatrutide vs Tirzepatide vs Semaglutide vs the Pill: The 2026 GLP-1 Field Guide
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.